Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
AEON Biopharma, Inc. Market Cap
Based on ratings from 0 stock analysts, the AEON Biopharma, Inc. stock price is expected to increase by 400% in 12 months. This is calculated by using the average 12-month stock price forecast for AEON Biopharma, Inc.. The lowest target is $5 and the highest is $5. Please note analyst price targets are not guaranteed and could be missed completely.
AEON Biopharma, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that AEON Biopharma, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of AEON.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Tsao HC Wainwright & Co. | Buy | $5 | Reiterates | Oct 1, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $5 | Maintains | Aug 14, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $6 | Reiterates | Jul 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $6 | Reiterates | May 30, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $6 | Maintains | May 15, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | May 6, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Reiterates | Apr 17, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Initiates | Aug 18, 2023 |
When did it IPO
2023
Staff Count
5
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Marc Forth
Market Cap
$43.5M
In 2023, AEON generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AEON's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 21 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AEON Biopharma shows a hammer chart pattern, suggesting support after recent losses. Upward earnings estimate revisions may indicate a potential trend reversal.
Why It Matters - The hammer pattern suggests potential support and a trend reversal for AEON, while rising earnings estimates indicate positive sentiment, which can drive stock prices higher.
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - AEON Biopharma, Inc. (NYSE: AEON) will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 1:30 PM ET.
Why It Matters - AEON Biopharma's presentation at a key investment conference could impact stock performance, signaling potential investor interest and updates on therapeutic developments.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Plans are underway to develop ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA).
Why It Matters - ABP-450's development as a biosimilar to BOTOX® could capture market share and increase revenue, impacting the competitive landscape and financial outlook for companies involved.
Wed, 29 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company anticipates its cash reserves will sustain operations until Q4 2024 and is exploring funding options for its late-stage clinical pipeline advancements.
Why It Matters - Sufficient cash reserves until Q4 2024 indicate financial stability, while evaluating funding options for late-stage projects may signal growth potential and future value creation.
Wed, 29 May 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AEON Biopharma, Inc. (AEON) is technically oversold, suggesting reduced selling pressure. Wall Street analysts have also raised earnings estimates, indicating a potential stock trend reversal.
Why It Matters - AEON Biopharma's oversold status and rising earnings estimates suggest a possible rebound, signaling a favorable investment opportunity and potential for price appreciation.
Tue, 14 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Phase 2 study of ABP-450 for chronic migraine did not meet primary or secondary endpoints, according to interim data analysis.
Why It Matters - Failure to meet primary and secondary endpoints in the Phase 2 study for ABP-450 raises concerns about the drug's viability, potentially impacting stock prices and investor confidence in the company.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
